4
Participants
Start Date
February 27, 2018
Primary Completion Date
July 9, 2024
Study Completion Date
July 9, 2024
BAX 888
Participants will receive a single peripheral IV infusion of BAX 888 in Cohort 1 and 2 Day 0.
Semmelweis Egyetem, Budapest
AKH - Medizinische Universität Wien, Vienna
Mount Sinai Medical Center, New York
Vivantes Klinikum im Friedrichshain, Berlin
Hôpital de la Timone, Marseille
Hospital Universitario La Paz, Madrid
Hospital Regional Universitario de Malaga, Málaga
Medical University of South Carolina (MUSC), Charleston
Hôpital Morvan, Brest
CHU Rennes - Hopital Pontchaillou, Rennes
Hospital Clinico Universitario de Salamanca, Salamanca
CHU Tours - Hôpital Trousseau, Tours
CHU de Nantes Site Hotel Dieu, Nantes
Cincinnati Children's Hospital Medical Center, Cincinnati
Hospital Universitari i Politecnic La Fe, Valencia
Hopital Jeanne de Flandre - CHU Lille, Lille
Klinikum der Johann Wolfgang Goethe-Universitaet, Frankfurt am Main
Groupement Hospitalier Est- Hôpital Louis Pradel, Bron
University of Colorado Hemophilia & Thrombosis Center, Aurora
Phoenix Childrens Hospital, Phoenix
Orthopaedic Hospital DBA Orthopaedic Hemophilia Treatment Center, Los Angeles
Hôpital Bicêtre, Le Kremlin-Bicêtre
UC Davis Medical Center, Sacramento
Gulf States Hemophilia and Thrombophilia Center, Houston
Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden
Hospital Universitari Vall d'Hebron, Barcelona
Baxalta Innovations GmbH, now part of Shire
INDUSTRY
Takeda Development Center Americas, Inc.
INDUSTRY
Baxalta now part of Shire
INDUSTRY